TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients 18 years and older with the diagnosis of disseminated superficial actinic porokeratosis.~Exclusion Criteria:~* Patients with allergies or contraindications to lovastatin or cholesterol~* Female patients currently pregnant or lactating.~* Female patients with plans to become pregnant.~* Patients actively taking approved forms of long-term contraception (oral contraceptives, implantable intrauterine devices, or other hormone eluting implants) will be allowed to participate as long as they have no plan to become pregnant during the course of the study. A urine pregnancy test will be administered to these patients to confirm that they can be included in the study.~* Inability or unwillingness of subject or legal guardian/representative to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Statin/Cholesterol Combination Group (Type: EXPERIMENTAL): This arm will utilize 2% cholesterol and 2% lovastatin ointment. It will be compounded by a pharmacist. Ointment will be applied on lesional skin with occlusion twice daily for 12 weeks.
- Statin Alone Group (Type: EXPERIMENTAL): This arm will utilize 2% lovastatin ointment. It will be compounded by a pharmacist. Ointment will be applied on lesional skin with occlusion twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult between 18 years and above~* Moderate to severe disease activity~* Negative pregnancy test for women of childbearing potential~* Use of reliable method of contraception (non-hormonal) by sexually active female patients~Exclusion Criteria:~* Patients who are pregnant or breastfeeding~* Patients taking biologic therapy or prednisolone \>7.5mg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Cetrorelix
- 2 (Type: PLACEBO_COMPARATOR): NaCl solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Registry Study of Berinert® in Normal Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any patient receiving CSL Behring's C1-esterase inhibitor~* Written informed consent (may not be required for some retrospective chart review cases)~Exclusion Criteria:~* Any patient participating in an HAE study using other C1-inhibitors than Berinert®

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Berinert (Type: None): Patients requiring treatment with Berinert®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Availability of volunteer for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.~2. Patients with metastatic breast cancer/advanced ovarian cancer having age within the range of between 18-55 years.~3. Subjects who had no evidence of underlying disease~4. Subjects who had signed written consent form~Exclusion Criteria:~1. Females who were pregnant, breastfeeding, or are likely to become pregnant~2. Subjects who had any medical condition (except metastatic breast cancer/advanced ovarian cancer) that could jeopardize their health or prejudice the results~3. Subjects deemed uncooperative or noncompliant~4. Smoking or consumption of any nicotine products

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- SPARC-08-038 (Type: EXPERIMENTAL): 2 mg/ml
- Ref-08-038 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age \> 7 years Residence in project village~Exclusion Criteria:~* persons treated with praziquantel within 2 weeks before recruitment

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with type 2 diabetes mellitus (T2DM)~* Have HbA1c between ≥7.5% and ≤11%~* Have been treated for at least 90 days prior to day of screening with once or twice daily basal insulin with or without stable dose of metformin ≥1500 mg/day and up to maximum approved dose per country specific approved label, sulfonylureas or dipeptidyl peptidase 4 inhibitors~* Be of stable weight (± 5%) for at least 90 days~* Have a BMI ≥23 kilograms per meter squared (kg/m²) and ≤45 kg/m² at screening~Exclusion Criteria~* Have type 1 diabetes mellitus~* Have had chronic or acute pancreatitis any time prior to study entry~* Have proliferative diabetic retinopathy or diabetic macular edema or nonproliferative diabetic retinopathy requiring immediate or urgent treatment~* Have disorders associated with slowed emptying of the stomach, have had any stomach surgeries for the purpose of weight loss, or are chronically taking drugs that directly affect gastrointestinal motility~* Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months~* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2~* Have been taking weight loss drugs, including over-the-counter medications during the last 3 months~* Have an estimated glomerular filtration rate \<30 mL/minute/1.73 m² \[for participants on metformin, estimated glomerular filtration rate \<45 mL/min/1.73 m2 (or lower than the country-specific threshold for using the protocol-required dose of metformin per local label)\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Tirzepatide (Type: EXPERIMENTAL): 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
- 10 mg Tirzepatide (Type: EXPERIMENTAL): 10 mg tirzepatide administered SC once a week.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): 15 mg tirzepatide administered SC once a week.
- Insulin Lispro (Type: ACTIVE_COMPARATOR): Insulin lispro 100 units per milliliter (U100) administered SC three times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Patients with treatment-requiring chronic lymphocytic leukemia (CLL)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Life expectancy \>6 months~Exclusion Criteria:~* Transformation to aggressive B-cell malignancy~* History of other malignancy unless the patient was treated with curative intent and has been in remission for more than 5 years prior to enrolment~* HIV or Hepatitis B positive unless clearly due to vaccination~* Inadequate liver or renal function~* Any coexisting medical or psychological condition that would preclude participation in the required study procedures~Additional exclusion criterion for Part 1:~* Any previous treatment for CLL except for up to 4 cycles of rituximab IV in combination with FC chemotherapy as first-line treatment for CLL~Additional exclusion criterion for Part 2:~* Any previous treatment for CLL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Has essential hypertension (diastolic blood pressure ≥ 95mm Hg and ≤ 119 mm Hg. For participants with diabetes or chronic kidney disease diastolic blood pressure must be ≥ 85 mm Hg and ≤ to 109 mm Hg.~2. Female participant is not of childbearing potential (eg, sterilized, postmenopausal).~3. Female participants of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~4. Clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) are within the reference range for the testing laboratory unless the results are deemed not clinically significant for inclusion into this study by the investigator.~Exclusion Criteria~1. Systolic blood pressure greater than 185 mm Hg.~2. Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:~3. Is hypersensitive to AII receptor blockers.~4. Recent history (within the last 6 months) of myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, cerebrovascular accident, or transient ischemic attack.~5. History of moderate to severe heart failure or hypertensive encephalopathy.~6. Has clinically significant cardiac conduction defects (eg, third-degree atrioventricular block, sick sinus syndrome).~7. Has secondary hypertension of any etiology.~8. Known or suspected unilateral or bilateral renal artery stenosis.~9. Has severe renal dysfunction or disease (based on calculated creatinine clearance \< 30 mL/min/1.73 m2) at Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azilsartan Medoxomil QD-Open Label Phase (Baseline - Week 26) (Type: EXPERIMENTAL): None
- Azilsartan Medoxomil QD - Double-Blind Phase (Week 26-32) (Type: EXPERIMENTAL): None
- Placebo QD - Double-Blind Phase (Week 26- 32) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Filtered Trial for Amlodipine Non-responder

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Essential hypertensive patients satisfying all of the following criteria;~2. Male or Female~3. Age \> 20 years~4. Outpatient~5. Patients who are able to stop current anti-hypertensive therapy at Visit 1 if taking any anti-hypertensive medications~6. Patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as Good Clinical Practice (GCP) and the Pharmaceutical Affairs Law.~Exclusion Criteria:~1. Taking four or more anti-hypertensive medications~2. Secondary hypertension~3. Mean seated diastolic blood pressure (DBP) \> 114 mmHg and/or mean seated systolic blood pressure (SBP) \> 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP \< 90 mmHg at Visit 3.~4. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias~5. Congestive heart failure patients with the New York Heart Association (NYHA) functional class III-IV~6. History of myocardial infarction or cardiac surgery within last 6 months~7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months~8. History of unstable angina within last 3 months~9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve~10. History of stroke or transient ischemic attack within last 6 months~11. History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal transplant or post-nephrectomy~12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors~13. Known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine -derived drugs~14. Hepatic and/or renal dysfunction~15. Diagnosed biliary atresia or cholestasis~16. Hyperkalemia~17. Dehydration~18. Sodium deficiency~19. Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (NSAIDs)~20. Patients who cannot change to the restricted administration and dosage during study period~21. Pre-menopausal women who meet any one of the following 1 - 3:~    * Pregnant or possibly pregnant (1)~   * Nursing (2)~   * Desire to become pregnant during study period (3)~22. Drug or alcohol dependency~23. Complication of malignant tumour or a disease requiring immunosuppressants~24. Compliance of \< 80% or \> 120% during the run-in period~25. Receiving any investigational therapy within 3 months~26. Judged to be inappropriate by the investigator or the sub-investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have diagnosis of EoE (based on consensus criteria)~* Have histologically confirmed active disease \>15 eosinophils/hpf in either distal or proximal esophagus within 12 weeks of screening visit~* Symptomatic (have experienced symptoms within the last month prior to enrollment)~* Proton pump inhibitor (PPI) confirmation~* Have a negative urine pregnancy test at screening if of childbearing potential~Exclusion Criteria:~* Have been treated with topical swallowed steroids within the last 2 months or systemic steroids within the last 3 months~* Have pathological eosinophilia in segments of the GI tract other than the esophagus determined by local review~* Have been diagnosed with a GI malabsorption disorder (i.e., Inflammatory bowel disease, Crohn's disease) or Celiac disease~* Are currently on dietary therapy strictly avoiding milk or on a 6FED~* Have concurrent H pylori gastritis or parasitic infection~* Have history of anaphylaxis to milk (with current avoidance of milk)~* Have previously failed strict dietary therapy clearly documented with one of these regimens or topical steroid treatment (i.e. have achieved histological remission of \<15 eos/hpf after having been on fluticasone or \>1mg budesonide per day).~* Use of investigational drugs within 4 weeks (one month) prior to enrollment~* Are concurrently receiving any of the prohibited medications for the study~* On immunotherapy for pollen (if not on maintenance therapy) or immunoglobulin-E (IgE) -mediated food allergy~* Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1-Food Elimination Diet (1FED) (Type: ACTIVE_COMPARATOR): Participants eliminate milk from the diet in Phase 1
- 6-Food Elimination Diet (6FED) (Type: ACTIVE_COMPARATOR): Participants eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 1
- 1FED Non-Responders (6FED) (Type: OTHER): Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 2
- 6FED Non-responders (SGC) (Type: OTHER): Participants that fail to respond to 6FED in Phase 1 administer swallowed glucocorticoids (SGC) (Flovent HFA) 880 mcg twice daily in Phase 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin A Supplementation in Newborns Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All live born children~Exclusion Criteria:~* Children who die prior to study staff visiting the home to enroll the child and deliver the assigned intervention.

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 2 Weeks
- Healthy Volunteers: t

Study Arms:
- Vitamin A (Type: ACTIVE_COMPARATOR): 48,000 IU vitamin A oral dose spread over 2 days as soon as possible after birth.
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>= 25 years of age~* Type 2 diabetes for \>= 1 year~* Hemoglobin A1c \>= 7.5% and \<=11%~* Diabetes managed by exercise and diet, prescription oral medication or an injectable incretin mimetic~Exclusion Criteria:~* Type 1 diabetes~* On any type of insulin therapy at start of study

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Control Group (ACG) (Type: OTHER): Participants in the Active Control Group received enhanced standard of care (more frequent clinic visits, free blood glucose meters and strips and point-of-care Hemoglobin A1c (HbA1c) test) for management of their Type 2 diabetes.
- Structured Testing Group (STG) (Type: EXPERIMENTAL): Participants in the Structured Testing Group in addition to enhanced standard of care for the treatment of their Type 2 diabetes used the ACCU-CHEK® 360° View blood glucose analysis system (Tool) to monitor glucose levels at least quarterly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete